California is currently home to 5602 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Los Angeles, San Francisco, San Diego and Sacramento. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)
Recruiting
The primary objective of this study is to characterize the safety and tolerability of loncastuximab tesirine in combination with polatuzumab vedotin, glofitamab, or mosunetuzumab, and to identify the maximum tolerated dose (MTD) and/or recommended dose for expansion (RDE) for the combinations.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/16/2025
Locations: University of California San Francisco - Fresno Center for Medical Education and Research, Clovis, California
Conditions: B-Cell Non-Hodgkin Lymphoma, Relapsed B-Cell Non-Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma
64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for Identification and Treatment of PSMA-expressing Metastatic Castrate Resistant Prostate Cancer (SECuRE)
Recruiting
The aim of this study is to determine the safety and efficacy of 67Cu-SAR-bisPSMA in participants with PSMA-expressing metastatic castrate resistant prostate cancer.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
06/16/2025
Locations: Stanford Cancer Institute, Stanford, California
Conditions: Prostatic Neoplasms, Castration-Resistant
SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Recruiting
This research study is studying a drug as a possible treatment for diagnosis of AML, BPDCN and high-risk MDS. The interventions involved in this study are: * SL-401 * Azacitidine * Venetoclax
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/16/2025
Locations: City of Hope, Duarte, California
Conditions: Acute Myeloid Leukemia, Myelodysplastic Syndrome, Blastic Plasmacytoid Dendritic Cell Neoplasm
National Collaborative to Improve Care of Children With Complex Congenital Heart Disease
Recruiting
The purpose of this initiative is to improve care and outcomes for infants with HLHS by expanding the NPC-QIC national registry to gather clinical care process, outcome, and developmental data on infants with HLHS between diagnosis and 12 months of age, by improving the use of standards into everyday practice across pediatric cardiology centers, and by engaging parents as partners in the process.
Gender:
ALL
Ages:
15 months and below
Trial Updated:
06/16/2025
Locations: Children's Hospital Los Angeles, Los Angeles, California
Conditions: Hypoplastic Left Heart Syndrome (HLHS)
Adolescents and Young Adults With Cancer: Their Preferred Involvement in Decision Making
Recruiting
The purpose of this mixed-methods study is to determine Adolescent and Young Adult (AYAs) decision making preferences post cancer diagnosis using vignettes designed to assess their preferred involvement in decisions about their cancer treatment and variables associated with these treatment decision-making (TDM) preferences.
Gender:
ALL
Ages:
Between 15 years and 29 years
Trial Updated:
06/15/2025
Locations: Stanford University, Palo Alto, California
Conditions: Adolescent Behavior
Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)
Recruiting
This is a Phase 3, open-label, randomized, clinical trial evaluating the efficacy and safety of gedatolisib plus fulvestrant and CDK4/6 Inhibitors for the treatment of patients with locally advanced or metastatic HR+/HER2- advanced breast cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/14/2025
Locations: Providence Medical Foundation, Fullerton, California
Conditions: Breast Cancer
The Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination With Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis After Reduced Intensity Conditioning and Peripheral Blood Stem Cell Transplantation
Recruiting
Background: Blood cancers (such as leukemias or lymphomas) often do not respond to standard treatments. A transplant of blood stem cells from a healthy donor can help people with these cancers. Sometimes these transplants cause serious side effects, including a common immunologic problem called graft-versus-host disease. A drug called cyclophosphamide given early after the transplant (post-transplantation cyclophosphamide, PTCy) can reduce these complications. But sometimes this drug has its ow... Read More
Gender:
ALL
Ages:
12 years and above
Trial Updated:
06/14/2025
Locations: City of Hope, Duarte, California
Conditions: Peripheral Blood Stem Cell Transplantation, Hematopoietic Stem Cell Transplantation
A Study of LY3867070 in Healthy Participants
Recruiting
The purpose of this study is to evaluate how well LY3867070 is tolerated and what side effects may occur in healthy participants. The study drug will be administered orally. Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
06/13/2025
Locations: Anaheim Clinical Trials, LLC, Anaheim, California
Conditions: Healthy
Safety Study of Roflumilast Cream 0.05% in Infants Aged 3 Months to Less Than 2 Years With Atopic Dermatitis
Recruiting
This study will assess the safety and tolerability of ARQ-151 cream 0.05% applied once a day for 4 weeks in infants with atopic dermatitis (eczema).
Gender:
ALL
Ages:
Between 3 months and 2 years
Trial Updated:
06/13/2025
Locations: Arcutis Clinical Study Site 209, Rancho Santa Margarita, California
Conditions: Atopic Dermatitis (Eczema)
A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate-To-Severe Asthma
Recruiting
The purpose of this clinical trial is to learn about the safety and effects of the study medicine (called PF-07275315) for the potential treatment of moderate-to-severe asthma. Asthma is a condition that makes it challenging to breathe, which negatively impacts the quality of life and functioning of people who are affected. This study is seeking participants who: * Are 18 to 70 years old * Have had moderate-to-severe asthma for at least 12 months that is not well controlled * Have been taking... Read More
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
06/13/2025
Locations: Antelope Valley Clinical Trials, Lancaster, California
Conditions: Asthma
EluPro Antibiotic-Eluting BioEnvelope Registry
Recruiting
A Multi-Center Registry Study Evaluating Participants Who Receive EluPro Antibiotic-Eluting BioEnvelope During CIED Implantation
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/13/2025
Locations: UC San Diego Health, La Jolla, California
Conditions: Cardiac Arrhythmias
A Study to Evaluate the Efficacy and Safety of Orally Administered VX-01
Recruiting
The goal of this clinical trial is to evaluate the efficacy, safety, pharmacokinetics (PK) and pharmacodynamics (PD) of VX-01 as stand-alone treatment for Diabetic Retinopathy of Non-Proliferative Type (NPDR). The primary objective of the study is to evaluate the efficacy of daily oral doses of VX-01 versus placebo following 52 weeks of treatment.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/13/2025
Locations: Retina-Vitreous Associates Medical Group, Beverly Hills, California
Conditions: Diabetic Retinopathy, NPDR - Non Proliferative Diabetic Retinopathy